H101溶瘤腺病毒联合长春瑞滨/顺铂一线治疗晚期非小细胞肺癌  

Oncolytic adenovirus H101 in combination with vinorelbine/cisplatin chemotherapy for advanced non-small cell lung cancer

作　　者：周彩存[1] 徐瑛[1] 倪健[1] 周崧雯[1] 徐建芳[1] 吕梅君[1] 王丽[1] 陈杰[2] 王智[2] 

机构地区：[1]同济大学附属上海市肺科医院肿瘤科,上海200433 [2]上海三维生物技术有限公司医学部,上海200001

出　　处：《肿瘤》2006年第7期613-617,共5页Tumor

摘　　要：目的:探讨溶瘤腺病毒H101瘤内注射联合长春瑞滨/顺铂(NP)治疗晚期非小细胞肺癌(NSCLC)的疗效与安全性。方法:病理学或细胞学确诊的初治NSCLC患者随机接受经皮肺穿剌瘤内注射H1011.5×1012病毒颗粒联合NP方案化疗(A组)或单纯NP方案化疗(B组)。治疗2个周期后进行一次评价疗效,随访无进展生存时间(TTP)和生存期。结果:A组19例可评价患者中,总体疗效部分缓解(PR)5例,疾病稳定(SD)10例,疾病进展(PD)4例;B组可评价17例中,PR3例,SD9例和PD5例。第1次评价疗效时,A组PD1例,而B组PD5例,B组治疗失败率显著高于A组(P<0.05)。2组生存曲线几乎相似,但A组6月、9月和1年生存率均要稍高于B组;A组中位TTP时间也较B组有所延长。A组副反应中,除了非感染发热外,其他不良反应与B组相似。A组有2例发生轻度气胸。结论:经皮肺穿剌瘤内注射H101联合NP方案治疗晚期NSCLC是可行、安全与有效的。Objective：To investigate the efficacy and safety of intratumoral injection of oncolytic adenovirus H101 in combination with vinorelbine/cispaltin chemotherapy （NP） in patients with advanced non-small cell lung cancer （NSCLC）. Methods： The NSCLC patients confirmed by cytological or pathological examination were randomized to receive intratumoral injection of adenovirus H101（1.5 × 10^12 viral particles） plus NP chemotherapy （Arm A） or only NP chemotherapy （Arm B）. Objective response was evaluated every two cycles and time to progression （TTP） and overall survival were followed up. Results： In evaluable 19 patients of Arm A,5 got partial response （PR） ,10 stable disease （SD） ,and 4 disease progression （PD）, while in evaluable 17 patients of Arm B,3 cases of PR,9 cases of SD,and 5 cases of PD. At the first time of response evaluation,there was 1 case of PD in Arm A,but 5 cases of PD in Arm B. Failure rate in Arm B was significantly higher than that in Arm A（P〈0.05）. Survival curves between the two arms were similar. Six month,9 month and 1 year survival rates were slightly higher and median TTP was also prolonged in Arm A. Except non-infectious fever,other adverse reactions of Arm A were similar to Arm B. There was only 2 patients developing mild pneumothorax in Arm A. Conclusion.. Intratumoral injection of H101 viral particles in combination with NP chemotherapy is feasible, effective, and safe in treatment of advanced NSCLC.

关 键 词：肺肿瘤 癌 非小细胞肺 腺病毒 人 抗肿瘤药 综合疗法 

分 类 号：R734.2[医药卫生—肿瘤]